UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Performance of the cobas HPV Test for the Triage of Atypical Squamous Cells of Undetermined Significance Cytology in Cervical Specimens Collected in SurePath

American journal of clinical pathology, 2017-11, Vol.148 (5), p.450-457

2017

Volltextzugriff (PDF)

De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening

Implementation science communications, 2021-09, Vol.2 (1), p.108-108, Article 108

2021

Volltextzugriff (PDF)

Conserved Methylation Patterns of Human Papillomavirus Type 16 DNA in Asymptomatic Infection and Cervical Neoplasia

Journal of Virology, 2004-12, Vol.78 (23), p.12762-12772

2004

Volltextzugriff (PDF)

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

Journal of clinical oncology, 2015-05, Vol.33 (13), p.1460-1466

2015

Volltextzugriff (PDF)

Racial and Ethnic Disparities in the Time to Ovarian Cancer Surgery in Patients at an Integrated Health Care Delivery System

Journal of the National Comprehensive Cancer Network, 2024-10, Vol.22 (8), p.549-555

2024

Volltextzugriff (PDF)

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

The lancet oncology, 2020-12, Vol.21 (12), p.1661-1672

2020

Volltextzugriff (PDF)

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor

Obstetrics and gynecology (New York. 1953), 2019-08, Vol.134 (2), p.424-424

2019

Volltextzugriff (PDF)

Cloning of a Surface Membrane Glycoprotein Specific for the Infective Form of Trypanosoma cruzi Having Adhesive Properties to Laminin

The Journal of biological chemistry, 1999-02, Vol.274 (6), p.3461-3468

1999

Volltextzugriff (PDF)

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5625-TPS5625

2023

Volltextzugriff (PDF)

Physicians' perception of the ability of primary high-risk HPV screening to detect cervical cancer: A survey study

Gynecologic oncology, 2020-11, Vol.159 (2), p.e24-e25

2020

Volltextzugriff (PDF)

Primary Human Papillomavirus Screening: Women’s Perceptions of New Cervical Cancer Screening Recommendations

Journal of women's health (Larchmont, N.Y. 2002), 2024-09

2024

Volltextzugriff (PDF)

30 Attenuation of COVID-19 infection among patients with endometrial and cervical cancer receiving immunotherapy

Gynecologic oncology reports, 2023-08, Vol.48, p.S17-S17

2023

Volltextzugriff (PDF)

Gene expression profiling of in vitro radiation resistance in cervical carcinoma: A feasibility study

Gynecologic oncology, 2005-10, Vol.99 (1), p.84-91

2005

Volltextzugriff (PDF)

FLORA-5: A phase III double blind placebo controlled multicenter clinical study of front-line chemo-immunotherapy (paclitaxel and carboplatin +/- oregovomab) in patients with advanced epithelial ovarian cancer (GOG-3035) (298)

Gynecologic oncology, 2022-08, Vol.166, p.S157

2022

Volltextzugriff (PDF)

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5606-TPS5606

2021

Volltextzugriff (PDF)

Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September 30, 2019, and January 1-September 30, 2020

MMWR. Morbidity and mortality weekly report, 2021-01, Vol.70 (4), p.109-113

2021

Volltextzugriff (PDF)

Cervical Cancer Screening: Patient Perspectives on Transitioning to Primary High-Risk Human Papillomavirus Testing Alone

Permanente journal, 2024-10, p.1-8

2024

Volltextzugriff (PDF)

FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5619-TPS5619

2022

Volltextzugriff (PDF)

Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary

Obstetrics and gynecology (New York. 1953), 2004-05, Vol.103 (5 Pt 2), p.1051-1054

2004

Volltextzugriff (PDF)

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor

Obstetrics and gynecology (New York. 1953), 2016-02, Vol.127 (2), p.222-225

2016

Volltextzugriff (PDF)

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

Investigational new drugs, 2004-11, Vol.22 (4), p.475-480

2004

Volltextzugriff (PDF)

TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A233-A234

2022

Volltextzugriff (PDF)

Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2 -wt patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6017-6017

2020

Volltextzugriff (PDF)

A study protocol for a cluster randomized pragmatic trial for comparing strategies for implementing primary HPV testing for routine cervical cancer screening in a large health care system

Contemporary clinical trials, 2023-01, Vol.124, p.106994-106994, Article 106994

2023

Volltextzugriff (PDF)

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Obstetrical & gynecological survey, 2021-03, Vol.76 (3), p.151-152

2021

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(36)
Buchkapitel
(1)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Performance of the cobas HPV Test for the Triage of Atypical Squamous Cells of Undetermined Significance Cytology in Cervical Specimens Collected in SurePath

De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening

Conserved Methylation Patterns of Human Papillomavirus Type 16 DNA in Asymptomatic Infection and Cervical Neoplasia

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

Racial and Ethnic Disparities in the Time to Ovarian Cancer Surgery in Patients at an Integrated Health Care Delivery System

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor

Cloning of a Surface Membrane Glycoprotein Specific for the Infective Form of Trypanosoma cruzi Having Adhesive Properties to Laminin

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study

Physicians' perception of the ability of primary high-risk HPV screening to detect cervical cancer: A survey study

Primary Human Papillomavirus Screening: Women’s Perceptions of New Cervical Cancer Screening Recommendations

30 Attenuation of COVID-19 infection among patients with endometrial and cervical cancer receiving immunotherapy

Gene expression profiling of in vitro radiation resistance in cervical carcinoma: A feasibility study

FLORA-5: A phase III double blind placebo controlled multicenter clinical study of front-line chemo-immunotherapy (paclitaxel and carboplatin +/- oregovomab) in patients with advanced epithelial ovarian cancer (GOG-3035) (298)

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study

Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September 30, 2019, and January 1-September 30, 2020

Cervical Cancer Screening: Patient Perspectives on Transitioning to Primary High-Risk Human Papillomavirus Testing Alone

FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study

Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study

Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2 -wt patients

A study protocol for a cluster randomized pragmatic trial for comparing strategies for implementing primary HPV testing for routine cervical cancer screening in a large health care system

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Suchergebnisse filtern